If granted, Tremfya will be approved to treat children ages six and under with severe plaque psoriasis and children ages five ...

Johnson & Johnson has announced the submission of two supplemental Biologics License Applications (sBLAs) to the U.S. Food ...

Johnson & Johnson today announced the submission of two supplemental Biologics License Applications (sBLAs) to the U.S. Food and Dr ...

The approval of Yesintek (ustekinumab-kfce), the sixth biosimilar to reference Stelara, will be used to treat patients with ...

The Food and Drug Administration (FDA) has approved Yesintek TM (ustekinumab-kfce), a biosimilar to Stelara ® (Ustekinumab), for the treatment of various chronic inflammatory diseases. Yesintek, ...

Topline results were announced from a phase 3 trial evaluating icotrokinra in patients with moderate to severe plaque psoriasis (PsO).

Yesintek is the latest Stelara biosimilar to gain FDA approval and it will be available in February 2025.

Johnson & Johnson announced the submission of two supplemental Biologics License Applications, sBLAs, to the U.S. Food and Drug ...

It is also less expensive than some of the newer psoriasis treatments. Vtama (tapinarof) cream, 1% is an aryl hydrocarbon receptor agonist that was approved in 2022 for the treatment of mild, moderate ...

The approval marks the sixth biosimilar to reference Stelara (ustekinumab), and it will be used to treat several immunology ...

Johnson & Johnson announced the submission of two supplemental Biologics License Applications to the FDA seeking approval of TREMFYA ...

"The approval of Sotyktu represents an exciting day for patients suffering from moderate-to-severe plaque psoriasis who are not satisfied with topical and conventional treatments," said Samit ...